 The observational study began on 01 November 2012 and is scheduled for a period of 10 years continued until 01 November 2022. The duration of the observational study for each patient is not fixed corresponding to the character of a non-interventional study. According to the underlying disease, characterized either acute or chronic, there are 2 and 3 observations within the treatment period, respectively. Documentation comprises the course of the underlying diseases by tracking of general and diseases-specific symptoms, drug compatibility by ADR assessment, concomitant medication or other treatment, health economic data, details of treatment regimen and standard epidemiological data. 